drug
lansoprazole DR
Marketedupdated 3mo agoby NATCO Pharma Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6all catalysts(10)
approval · 10
Jun 7, 2016
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Jan 25, 2017
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
May 9, 2017
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Nov 15, 2017
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Nov 30, 2017
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Nov 30, 2017
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Apr 9, 2019
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Nov 20, 2020
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Nov 1, 2022
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Mar 11, 2026
approval
LANSOPRAZOLE — FDA approval
lansoprazole DR
→
Trials studying lansoprazole DR
- phase4Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer
- N/AFexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
- phase2A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- phase2A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
- phase3A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
- phase3A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
- phase3The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis
- phase2Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 21, 2036
~9.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Apr 21, 2036formulationUS 11077055
- Apr 21, 2036formulationUS 11986554
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that